TY - JOUR T1 - EML4-ALK V3 drives cell migration through NEK9 and NEK7 kinases in non-small-cell lung cancer JF - bioRxiv DO - 10.1101/567305 SP - 567305 AU - Laura O’Regan AU - Giancarlo Barone AU - Rozita Adib AU - Chang Gok Woo AU - Hui Jeong Jeong AU - Emily L. Richardson AU - Mark W. Richards AU - Patricia A.J. Muller AU - Spencer J. Collis AU - Dean A. Fennell AU - Jene Choi AU - Richard Bayliss AU - Andrew M. Fry Y1 - 2019/01/01 UR - http://biorxiv.org/content/early/2019/03/04/567305.abstract N2 - EML4-ALK is an oncogenic fusion present in ∼5% lung adenocarcinomas. However, distinct EML4-ALK variants differ in the length of the EML4 microtubule-associated protein encoded within the fusion and are associated with a poorly understood variability in disease progression and therapeutic response. Here, we show that EML4-ALK variant 3, which is linked to accelerated metastatic spread and worse patient outcome, causes microtubule stabilization, formation of extended cytoplasmic protrusions, loss of cell polarity and increased cell migration. Strikingly, this is dependent upon the NEK9 kinase that interacts with the N-terminal region of EML4. Overexpression of wild-type EML4, as well as constitutive activation of NEK9, also perturbs cell morphology and accelerates cell migration in a manner that requires the downstream kinase NEK7 but not ALK activity. Moreover, elevated NEK9 is associated in patients with EML4-ALK V3 expression, as well as reduced progression-free and overall survival. Hence, we propose that EML4-ALK V3 promotes microtubule stabilization through recruitment of NEK9 and NEK7 to increase cell migration and that this represents a novel actionable pathway that drives disease progression in lung cancer. ER -